Advanced Therapy Medicinal Products Market to Reach $147.54 Billion by 2035

Advanced Therapy Medicinal Products (ATMP) market was valued at $28.5 billion in 2025 and is projected to reach $147.4 billion by 2035, growing at a CAGR of 17.9% during 2026–2035. Advanced Therapy Medicinal Products include gene therapy, cell therapy, tissue-engineered products, and combined ATMPs that integrate biological components with medical devices. These therapies are primarily used in the treatment of oncology, rare genetic disorders, cardiovascular diseases, neurological conditions, and immunological disorders. ATMPs are developed through advanced biotechnological processes involving genetic modification, cellular engineering, and regenerative medicine approaches. ATMPs play an indispensable role in modern healthcare by offering targeted, personalized, and potentially curative treatments. During treatment, these therapies act at the molecular or cellular level to repair, replace, or regenerate damaged tissues and cells. Governments across major economies are increasingly supporting domestic biopharmaceutical innovation through funding programs, regulatory acceleration pathways, and infrastructure development. These efforts are aimed at enhancing local manufacturing capabilities, encouraging clinical research, and ensuring a stable supply of advanced therapies.

Browse the full report description of “Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report, By Product Type (Gene Therapy, Cell Therapy, Tissue Engineered Products, Combined ATMPs), By Therapy Type (Autologous, Allogeneic), By Technology Platform (Viral Vector-Based, Non-Viral Delivery Systems, Gene Editing), By Application (Oncology, Rare Genetic Disorders, Cardiovascular, Neurological, Musculoskeletal, Ophthalmology, Immunological), By End User (Hospitals, Specialty Clinics, Research Institutes, Academic Medical Centers), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/advanced-therapy-medicinal-products-market

For instance, in March 2025, the U.S. Food and Drug Administration (FDA) expanded its Cell and Gene Therapy regulatory support programs to accelerate approvals and strengthen clinical development pipelines. The agency reported that over 30 ATMP-related products have been approved, with more than 1,000 clinical trials currently ongoing. Additionally, the European Medicines Agency (EMA) strengthened its Priority Medicines (PRIME) scheme in 2024 to fast-track innovative therapies addressing unmet medical needs. According to data from the National Institutes of Health (NIH), more than 300 million people globally are affected by rare diseases, significantly driving demand for advanced therapies.

Under current market dynamics, gene therapy accounts for the largest share due to increasing approvals and strong clinical pipelines, followed by cell therapy and tissue-engineered products. Autologous therapies dominate the therapy type segment owing to a lower risk of immune rejection, while allogeneic therapies are gaining traction due to scalability and cost efficiency. Viral vector-based technologies lead the technology platform segment, whereas gene editing technologies are emerging rapidly with advancements in precision medicine. Oncology represents the largest application segment, followed by rare genetic disorders and neurological diseases, reflecting the growing adoption of CAR-T and gene-modified therapies. Hospitals and academic medical centers remain the leading end users due to their advanced infrastructure and research capabilities.

To facilitate the successful implementation and commercialization of ATMPs, regulatory frameworks include the following strategic initiatives:

• Regulatory Fast-Track Programs – Accelerated approval pathways for innovative therapies addressing unmet medical needs
• Public Funding & Grants – Government-backed funding to support clinical trials and R&D activities
• Manufacturing Scale-Up Support – Investments in bio manufacturing infrastructure to enable large-scale production
• International Collaboration – Cross-border partnerships to enhance research, innovation, and market access

Recent Development

• In October 2024, the US Food and Drug Administration granted RMAT designation to Kite Pharma for Yescarta (axicabtagene ciloleucel). The therapy is being evaluated as a first-line treatment for adults with high-risk large B-cell lymphoma (LBCL). This applies to patients showing a positive PET scan after two cycles of chemoimmunotherapy. The designation aims to accelerate development for this aggressive cancer with high relapse rates and poor survival outcomes.

• In 2023, Cell and Gene Therapy Catapult, supported by Scottish Enterprise, launched a new collaboration network in Scotland to strengthen the Advanced Therapy Medicinal Products (ATMP) ecosystem. The initiative aims to enhance partnerships between industry, academia, and research institutions, promote knowledge sharing, and support ATMP development and manufacturing.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product Type
  • By Therapy Type
  • By Technology Type
  • By Application
  • By End Users
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Novartis AG, Gilead Sciences Inc, Bristol Myers Squibb, Johnson and Johnson, Roche Holding AG, among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Advanced Therapy Medicinal Products Market Report Segment

 By Product Type

• Gene Therapy
• Cell Therapy
• Tissue Engineered Products
• Combined ATMPs (Device + Biological components)

 By Therapy Type

• Autologous Therapies (patient-derived cells)
• Allogeneic Therapies (donor-derived cells)

 By Technology Platform

• Viral Vector-Based Technologies
• Non-Viral Delivery Systems
• Gene Editing Technologies

By Application / Therapeutic Area

• Oncology
• Rare Genetic Disorders
• Cardiovascular Diseases
• Neurological Disorders
• Musculoskeletal Disorders
• Ophthalmology
• Immunological Disorders

By End User

• Hospitals
• Specialty Clinics
• Research Institutes
• Academic Medical Centers

Global Advanced Therapy Medicinal Products Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/advanced-therapy-medicinal-products-market